BA
IONS icon

BKS Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

BKS Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,000
Closed -$230K – 158
2015
Q2 		$230K Buy
+4,000
New +$254K 0.11% 133

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BKS Advisors's IONS Position: Q3 2015 in Review

BKS Advisors sold out of Ionis Pharmaceuticals (IONS) in Q3 2015, closing a stake of 4,000 shares — an estimated $230K sold.

BKS Advisors first reported a position in IONS in Q2 2015 and held it in 1 quarter. The position peaked at $230K in Q2 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q3 2015.

  • BKS Advisors reported no remaining Ionis Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • BKS Advisors sold 4,000 Ionis Pharmaceuticals shares in Q3 2015, an estimated $230K.
  • BKS Advisors first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • BKS Advisors's Ionis Pharmaceuticals position peaked at $230K in Q2 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2015.

Based on BKS Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.